Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open Label, First in Human Phase I Dose Escalation Study of Single Agent RO5503781, a Small Molecule MDM2 Antagonist, Administered Orally in Patients With Advanced Malignancies, Except Leukemia.

Next Previous
X
Search
Trial Profile

A Multi-center, Open Label, First in Human Phase I Dose Escalation Study of Single Agent RO5503781, a Small Molecule MDM2 Antagonist, Administered Orally in Patients With Advanced Malignancies, Except Leukemia.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idasanutlin (Primary)
  • Indications Cancer; Chondrosarcoma; Colorectal cancer; Leiomyosarcoma; Malignant melanoma; Mesothelioma; Sarcoma; Testicular cancer
  • Focus Adverse reactions; First in man
  • Sponsors Roche

    • Most Recent Events

    • 28 Jun 2021 Results assessing maximum tolerated dose (MTD), characterize dose-limiting toxicity (DLT), and explore the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical responses with idasanutlin with different dosing schedules published in the Investigational New Drugs
    • 08 Dec 2020 Results investigating the contribution of Idasanutlin exposure variability to those findings, in particular, the relationship between exposure and toxicity and efficacy in pts with AML from NCT02545283, NCT01773408, NCT01462175 and NCT03287245 presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
    • 04 Aug 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top